YANTRIA
DEAD

Serial Number

87155697

Owner

ALLERGAN HOLDINGS UNLIMITED COMPANY

Filing Date

Aug 30, 2016

Add to watchlist:

No watchlists yet
View on USPTO

YANTRIA Trademark

Serial Number: 87155697

YANTRIA is a trademark filed by ALLERGAN HOLDINGS UNLIMITED COMPANY on August 30, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN HOLDINGS UNLIMITED COMPANY (10 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
DUBLIN 17 , IE

Entity Type: 99

Trademark Details

Filing Date

August 30, 2016

Registration Date

Not Registered

Published for Opposition

January 10, 2017

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 12, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 12, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 18, 2019 EXRA
SOU EXTENSION 5 GRANTED
Jul 17, 2019 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 17, 2019 AITU
SOU EXTENSION 5 FILED
Jul 15, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 15, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 2, 2019 EXRA
SOU EXTENSION 4 GRANTED
Feb 28, 2019 EX4G
SOU EXTENSION 4 FILED
Feb 28, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 28, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 7, 2018 EXRA
SOU EXTENSION 3 GRANTED
Sep 5, 2018 EX3G
SOU EXTENSION 3 FILED
Sep 5, 2018 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 5, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 31, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jan 29, 2018 EX2G
SOU EXTENSION 2 FILED
Jan 29, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 29, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 16, 2017 EXRA
SOU EXTENSION 1 GRANTED
Aug 14, 2017 EX1G
SOU EXTENSION 1 FILED
Aug 14, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 14, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 8, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 10, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jan 10, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 21, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 8, 2016 CNSA
ASSIGNED TO EXAMINER
Dec 8, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 6, 2016 NWOS
NEW APPLICATION ENTERED
Sep 2, 2016 NWAP